SAN FRANCISCO , Aug. 23, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced publication of the design and preclinical characterization of its lead product candidate, AG10, in the Journal of Medicinal Chemistry (
SAN FRANCISCO , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today reported its financial results
SAN FRANCISCO , June 22, 2018 /PRNewswire/ -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced the closing of its initial public
SAN FRANCISCO , June 19, 2018 /PRNewswire/ -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced the pricing of its initial public
SAN FRANCISCO, May 3, 2018 /PRNewswire/ -- Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR
Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials SAN FRANCISCO, April 5, 2018 /PRNewswire/ -- Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel
SAN FRANCISCO, March 20, 2018 /PRNewswire/ -- Eidos Therapeutics, a clinical stage biopharmaceutical company developing AG10, a novel precision medicine for transthyretin (TTR) amyloidosis (ATTR), today announced that it will host a symposium regarding TTR stabilization at the 16th International
SAN FRANCISCO, Jan. 5, 2018 /PRNewswire/ -- Eidos Therapeutics , a clinical stage biopharmaceutical company, today announced that Neil Kumar, Ph.D., the company's chief executive officer, will present a company overview at the 36 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 th
